Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 7NSCLC 3Adenocarcinoma of Lung 2Neoplasm, Residual 1Multiple Primary Lung Cancers 1Meningeal Carcinomatosis 1EGF-R Positive Non-Small Cell Lung Cancer 1Carcinoma 1Adenocarcinoma 1

Interventions

Methotrexate 3Bevacizumab 3osimertinib 2aumolertinib 2Pemetrexed 2paclitaxel-Angiopep-2 conjugate 1nimotuzumab 1lorlatinib 1glutathione pegylated liposomal doxorubicin 1eribulin 1envafolimab 1durvalumab 1camrelizumab 1aflutinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Magnetic Resonance Spectroscopy 1Immunoenzyme Techniques 1Endostatins 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Meningeal Carcinomatosis × aflutinib × Clear all
NCT05813522 2023-04-14

Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
30 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡